Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Operating Leases (2022 - 2025)

Oncology Institute (TOI) has disclosed Operating Leases for 4 consecutive years, with $27.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 12.92% year-over-year to $27.4 million, compared with a TTM value of $27.4 million through Sep 2025, down 12.92%, and an annual FY2024 reading of $23.2 million, down 12.32% over the prior year.
  • Operating Leases was $27.4 million for Q3 2025 at Oncology Institute, down from $28.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $31.4 million in Q3 2024 and bottomed at $14.6 million in Q2 2022.
  • Average Operating Leases over 4 years is $24.8 million, with a median of $26.0 million recorded in 2023.
  • The sharpest move saw Operating Leases skyrocketed 82.34% in 2023, then fell 12.92% in 2025.
  • Year by year, Operating Leases stood at $22.1 million in 2022, then increased by 20.06% to $26.5 million in 2023, then fell by 12.32% to $23.2 million in 2024, then rose by 17.8% to $27.4 million in 2025.
  • Business Quant data shows Operating Leases for TOI at $27.4 million in Q3 2025, $28.1 million in Q2 2025, and $28.4 million in Q1 2025.